Sep 8, 2026 06:55AM
Aug 31, 2026 05:32AM
Jul 20, 2026 04:36PM
Jul 20, 2026 11:36AM
Jun 22, 2026 02:53PM
May 12, 2026 08:11AM
May 7, 2026 07:27AM NewAmsterdam Pharma Company N.V. (NAMS) reported Q1 Revenue
Mar 18, 2026 03:52PM
Feb 19, 2026 09:45AM
Feb 19, 2026 07:55AM
Jan 9, 2026 08:01AM
Jan 6, 2026 04:33AM
Dec 8, 2025 07:32AM
Nov 6, 2025 04:22AM NewAmsterdam Pharma Co NV (NAMS) PT Raised to $45 at Leerink Partners
Nov 5, 2025 03:59PM
Oct 20, 2025 07:08AM
Oct 6, 2025 04:32AM
Aug 25, 2025 05:13AM
Aug 18, 2025 08:02AM
Aug 11, 2025 08:23AM
Aug 6, 2025 10:18AM TD Cowen Reiterates Buy Rating on NewAmsterdam Pharma Co NV (NAMS)
Jul 30, 2025 08:26AM
Jul 17, 2025 06:30AM
Jun 17, 2025 05:18AM
Jun 12, 2025 07:22AM
Jun 12, 2025 07:15AM
Jun 9, 2025 04:06PM
Jun 9, 2025 07:05AM NewAmsterdam Pharma (NAMS) Announces Positive Topline Alzheimer’s Disease Data from BROADWAY Trial
Jun 4, 2025 06:53AM
Jun 3, 2025 05:52AM
May 7, 2025 07:15AM
Apr 17, 2025 04:02PM
Feb 27, 2025 07:18AM
Jan 13, 2025 12:50PM
Jan 10, 2025 08:03AM NewAmsterdam Pharma (NAMS) Highlights 2024 Achievements and Outlines 2025 Strategic Priorities
Jan 3, 2025 08:23AM
Dec 30, 2024 06:06AM
Dec 11, 2024 07:15AM
Dec 10, 2024 04:36PM
Dec 10, 2024 07:00AM
Nov 20, 2024 04:10PM
Nov 20, 2024 07:01AM NewAmsterdam Pharma (NAMS) Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with AS
Nov 19, 2024 07:57AM
Oct 21, 2024 07:14AM
Sep 23, 2024 07:20AM
Sep 7, 2024 08:00PM
Aug 27, 2024 08:18AM
Jul 29, 2024 08:06AM
Jul 26, 2024 04:01PM NewAmsterdam Pharma (NAMS) to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday
Jul 18, 2024 08:06AM

460,581 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All